Welcome to Helix Talk, an educational podcast for healthcare students and providers covering real-life clinical pearls, professional pharmacy topics, and drug therapy discussions.

This podcast is provided by pharmacists and faculty members at Rosal Franklin University College of Pharmacy.

This podcast contains general information for educational purposes only. This is not professional

advice and should not be used in lieu of obtaining advice from a qualified health care provider.

And now on to the show.

Welcome to Helix Talk episode 65. I'm your co-host Dr. Kane. I'm Dr. Schumann.

And I'm Dr. Patel. In today's episode is entitled Advanced Hypertension Ninja Skills with some of the oldest blood pressure

medications.

Today we'll be focusing on three blood pressure medications that are still used in clinical

practice but are definitely not first line and really what clinicians need to know about

these three medications in terms of why they're not on the radar in terms of first line and really what clinicians need to know about these three medications

in terms of why they're not on the radar in terms of first line therapies and then also what to

know about them particularly in terms of the side effect profile of those medications.

So we're going to talk about the clonidine, the metadopa, and monoxidil at the great length.

And I think it's important to kind of step back for a second and think about who decides

what is the first line anti-hypertensive and what criteria do they use.

And if we go back literally two decades, we're looking at 1997, this is when JNC6 came out.

We're all the way up to JNC 8 right now.

But what did JNC6 tell us about preferred

antihypertensis at that time? So what they said is for uncomplicated hypertension, first

line therapy there is going to be beta blockers or thyside diuretics. Beta blockers? Yeah, so

again, that's a great point. So that's something now that really is with these later guidelines,

...